Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neuro-oncology · Glioma

Decoding Your Glioma Pathology Report: IDH, 1p/19q, and WHO Grades

At a Glance

A modern glioma pathology report uses DNA markers to determine your tumor's behavior. Key markers like IDH mutation status, 1p/19q co-deletion, and MGMT methylation classify the exact tumor type, help predict its growth rate, and guide your care team in choosing the best targeted treatments.

Your pathology report is the definitive blueprint of your tumor’s biology. In the past, doctors relied solely on how cells looked under a microscope, but the 2021 WHO Classification now uses the tumor’s DNA to determine its name and its behavior [1][2]. Understanding these molecular markers helps you and your care team choose the most effective treatment strategy [3].

The Core Markers: IDH and 1p/19q

The first branch in the “decision tree” of your diagnosis is the IDH mutation status.

  • Wildtype (Normal): This means your cells have the normal version of the IDH gene [3]. In adults, an IDH-wildtype diffuse glioma is now almost always classified as a Glioblastoma (Grade 4), which is more aggressive and requires intensive treatment [4][2]. While “normal” sounds positive, a wildtype status in this context means the tumor lacks the IDH mutation and is instead being driven by other, more aggressive genetic pathways.
  • Mutant: This means the IDH gene has a specific change [3]. Generally, IDH-mutant tumors grow more slowly and have a better overall outlook than wildtype tumors [5][6].

If a tumor is IDH-mutant, the next marker is 1p/19q co-deletion. This looks at whether two specific pieces of the tumor’s chromosomes are missing [7].

  • Co-deleted: If these pieces are missing, the tumor is an Oligodendroglioma [8]. These often respond very well to chemotherapy [9].
  • Non-codeleted: If these pieces are present, the tumor is an Astrocytoma [8].

Additional Key Findings

  • MGMT Promoter Methylation: This is a “predictor” marker [5]. If your tumor is MGMT methylated, it is more likely to be sensitive to common chemotherapy drugs like temozolomide [10].
  • CDKN2A/B Deletion: This is a critical “upgrade” marker for IDH-mutant astrocytomas [11]. If this specific DNA piece is missing, the tumor is automatically graded as a Grade 4, even if it looks like a lower grade under the microscope [12][13].
  • ATRX and TERT: ATRX loss is common in astrocytomas, while TERT mutations are hallmarks of both oligodendrogliomas and IDH-wildtype glioblastomas [14][15][16].

The WHO Grading Scale

The World Health Organization (WHO) assigns a grade from 1 to 4 to describe how aggressive the tumor is likely to be [17].

Grade Description Typical Behavior
1 Low Grade Often considered “benign” or “circumscribed” (like pilocytic astrocytomas); mostly affects younger patients and surgical removal can sometimes be curative.
2 Low Grade “Diffuse” tumors with slower growth, but a higher chance of coming back or evolving into a higher grade over time [18].
3 High Grade “Malignant” or faster-growing cells; usually requires more aggressive treatment like radiation or chemo.
4 High Grade The most aggressive; these tumors grow quickly and require intensive combination therapy [2].

(Note: The IDH and 1p/19q rules discussed primarily apply to Grade 2-4 diffuse gliomas.)

Report Completeness Checklist

Ensure your pathology report includes these “Essential Four” molecular markers. If any are missing, ask your doctor if they have been ordered or are necessary for your specific case:

  1. IDH Mutation Status (Mutant or Wildtype) [19]
  2. 1p/19q Co-deletion Status (Present or Absent) [20]
  3. MGMT Promoter Methylation Status (Methylated or Unmethylated) [21]
  4. ATRX Status (Retained or Lost) [14]

Return to Home

Common questions in this guide

What does IDH-mutant mean on my glioma pathology report?
An IDH-mutant result means your tumor's DNA has a specific genetic change. Generally, IDH-mutant gliomas grow more slowly and have a better overall outlook compared to IDH-wildtype tumors, which tend to be more aggressive.
What is the difference between an astrocytoma and an oligodendroglioma?
Both are types of gliomas, but they have different DNA signatures. If an IDH-mutant tumor also has a 1p/19q co-deletion, it is classified as an oligodendroglioma, which often responds well to chemotherapy. If the 1p/19q co-deletion is missing, it is an astrocytoma.
Why is MGMT promoter methylation important?
MGMT promoter methylation is a predictive molecular marker found in the tumor's DNA. If your tumor is MGMT methylated, it means it is more likely to respond well to common chemotherapy drugs like temozolomide.
Do WHO grades depend on how the cells look or their DNA?
Under the 2021 WHO Classification, tumor grading relies heavily on the tumor's DNA in addition to how the cells look. For example, a CDKN2A/B genetic deletion automatically upgrades an IDH-mutant astrocytoma to a highly aggressive Grade 4, even if it looks like a lower grade under the microscope.
What are the essential molecular markers my glioma report should include?
A complete pathology report for a diffuse glioma should typically include four essential molecular markers. These are your IDH mutation status, 1p/19q co-deletion status, MGMT promoter methylation status, and ATRX status.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my report include results for the IDH mutation, 1p/19q codeletion, and MGMT promoter methylation?
  2. 2.If my tumor is an IDH-mutant astrocytoma, was it tested for CDKN2A/B deletion?
  3. 3.How do these specific molecular markers change the treatment options you are recommending?
  4. 4.Does the WHO grade on my report (1–4) come from what the cells look like, or from their DNA signature?
  5. 5.Should I have any further genetic or molecular testing performed on this sample?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Classification and Diagnosis of Adult Glioma: A Scoping Review.

    Byun YH, Park CK

    Brain & NeuroRehabilitation 2022; (15(3)):e23 doi:10.12786/bn.2022.15.e23.

    PMID: 36742083
  2. 2

    Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.

    Kurokawa R, Kurokawa M, Baba A, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2022; (42(5)):1474-1493 doi:10.1148/rg.210236.

    PMID: 35802502
  3. 3

    Review of the Recent Changes in the WHO Classification for Pediatric Brain and Spinal Cord Tumors.

    Halfpenny AM, Wood MD

    Pediatric neurosurgery 2023; (58(5)):337-355 doi:10.1159/000528957.

    PMID: 36617415
  4. 4

    The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.

    Perez A, Huse JT

    Current neurology and neuroscience reports 2021; (21(12)):67 doi:10.1007/s11910-021-01153-8.

    PMID: 34817712
  5. 5

    The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.

    Kurdi M, Shafique Butt N, Baeesa S, et al.

    Pathology oncology research : POR 2021; (27()):1609778 doi:10.3389/pore.2021.1609778.

    PMID: 34257620
  6. 6

    Characterization of gliomas: from morphology to molecules.

    Ferris SP, Hofmann JW, Solomon DA, Perry A

    Virchows Archiv : an international journal of pathology 2017; (471(2)):257-269 doi:10.1007/s00428-017-2181-4.

    PMID: 28674742
  7. 7

    Molecular classification of gliomas.

    Masui K, Mischel PS, Reifenberger G

    Handbook of clinical neurology 2016; (134()):97-120.

    PMID: 26948350
  8. 8

    Brain tumour genetic network signatures of survival.

    Ruffle JK, Mohinta S, Pombo G, et al.

    Brain : a journal of neurology 2023; (146(11)):4736-4754 doi:10.1093/brain/awad199.

    PMID: 37665980
  9. 9

    HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.

    Felix M, Friedel D, Jayavelu AK, et al.

    Neuro-oncology 2022; (24(12)):2121-2132 doi:10.1093/neuonc/noac111.

    PMID: 35511748
  10. 10

    Prognostic value of O 6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.

    Lam K, Eldred BSC, Kevan B, et al.

    Neuro-oncology advances 2022; (4(1)):vdac030 doi:10.1093/noajnl/vdac030.

    PMID: 35386566
  11. 11

    Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.

    Fortin Ensign SP, Jenkins RB, Giannini C, et al.

    Neuro-oncology 2023; (25(1)):28-36 doi:10.1093/neuonc/noac205.

    PMID: 35973817
  12. 12

    A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.

    Wetzel EA, Nohman AI, Hsieh AL, et al.

    Journal of neuro-oncology 2025; (171(2)):373-381 doi:10.1007/s11060-024-04852-7.

    PMID: 39432026
  13. 13

    Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma.

    Huang LE

    Biomedicines 2022; (10(2)) doi:10.3390/biomedicines10020246.

    PMID: 35203456
  14. 14

    Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.

    Ferreira MSV, Sørensen MD, Pusch S, et al.

    Journal of neuro-oncology 2020; (147(1)):1-14 doi:10.1007/s11060-020-03394-y.

    PMID: 31960234
  15. 15

    Correlation between IDH, ATRX, and TERT promoter mutations in glioma.

    Ohba S, Kuwahara K, Yamada S, et al.

    Brain tumor pathology 2020; (37(2)):33-40 doi:10.1007/s10014-020-00360-4.

    PMID: 32227259
  16. 16

    Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria.

    Lee Y, Park CK, Park SH

    Cancers 2024; (16(11)) doi:10.3390/cancers16112032.

    PMID: 38893152
  17. 17

    IDH mutant astrocytoma: biomarkers for prognostic stratification and the next frontiers.

    Brandner S, Jaunmuktane Z

    Neuropathology and applied neurobiology 2019; (45(2)):91-94 doi:10.1111/nan.12521.

    PMID: 30326147
  18. 18

    Canine Gliomatosis Cerebri: Morphologic and Immunohistochemical Characterization Is Supportive of Glial Histogenesis.

    Rissi DR, Donovan TA, Porter BF, et al.

    Veterinary pathology 2021; (58(2)):293-304 doi:10.1177/0300985820980704.

    PMID: 33357125
  19. 19

    Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH.

    de Biase D, Acquaviva G, Visani M, et al.

    The Journal of molecular diagnostics : JMD 2021; (23(9)):1185-1194 doi:10.1016/j.jmoldx.2021.06.004.

    PMID: 34186176
  20. 20

    Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.

    Nishikawa T, Watanabe R, Kitano Y, et al.

    Brain tumor pathology 2022; (39(1)):14-24 doi:10.1007/s10014-021-00418-x.

    PMID: 34826036
  21. 21

    Clinical Profile, Pathology, and Molecular Typing of Gliomas with Oligodendroglial Morphology: A Single Institutional Experience.

    Lavanya G, Uppin MS, Alugolu R, et al.

    Neurology India 2022; (70(3)):1020-1024 doi:10.4103/0028-3886.349641.

    PMID: 35864633

This page explains glioma pathology terminology for educational purposes only. Your neuro-oncologist and pathologist are the best sources for interpreting your specific biopsy or tumor report.

Get notified when new evidence is published on Glial tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.